Providers

Latest News

ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

July 31st 2025

Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).

Gene therapy appears to be a promising approach for a subset of genetic deafness. | Image credit: NathanDeverycom - stock.adobe.com
Progress and Challenges With Gene Therapy in Hereditary Hearing Loss

July 31st 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

Following an investigation, the FDA confirmed that shipments of delandistrogene moxeparvovec can resume. | Image Credit: immimagery - stock.adobe.com
FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

July 31st 2025

HCC is the most common type of liver cancer, and it typically occurs in patients with chronic liver conditions. | Image Credit: Crystal light - stock.adobe.com
TACE Plus SBRT Effective in Large Tumors Caused by HCC

July 30th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo